3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
48
Lymphoma, Large B-Cell, Diffuse
36
Multiple Myeloma
33
Burkitt Lymphoma
32
Lymphoma
30
Leukemia, Myeloid, Acute
29
Lymphoma, Non-Hodgkin
28
Recurrence
26
Breast Neoplasms
26
Neoplasms
23
Lymphoma, B-Cell
23
Myelodysplastic Syndromes
20
Lymphoma, Follicular
20
Leukemia, Lymphocytic, Chronic, B-Cell
20
Hodgkin Disease
17
Triple Negative Breast Neoplasms
16
Leukemia
16
Ovarian Neoplasms
15
Hematologic Neoplasms
15
Neuroblastoma
14
Melanoma
14
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
12
Pancreatic Neoplasms
12
Lymphoma, Mantle-Cell
12
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
12
Leukemia, Biphenotypic, Acute
10
Sarcoma
9
Osteosarcoma
9
Neoplasm Metastasis
9
Lymphoma, B-Cell, Marginal Zone
9
Interventions
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
balstilimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
Cyclophosphamide
×
90 days
×
Clear all
No trials found.